Literature DB >> 8602874

Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion.

T Chu1, Y Kumagai, E W DiStefano, A K Cho.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA) affects both dopamine and serotonin (5-HT) systems. One of its acute actions is to cause a reversible fall in steady-state brain 5-HT concentrations. To investigate the chemical basis of this acute effect, the brain levels of the parent compound and three major metabolites, 3,4- 3,4-methylenedioxyamphetamine (MDA), 3,4-dihydroxymethamphetamine (DHMA) and 6-hydroxy-3,4-methylenedioxymethamphetamine (6-OHMDMA), were monitored, together with 5-HT levels, over a period of 6 hr in male Sprague-Dawley (SD) rats. The temporal relationships between drug concentrations of both stereoisomers and depletions were evaluated first. There was no correlation between the concentrations of the compounds measured and the extent of 5-HT depletion. Brain levels of MDMA and MDA were higher than plasma levels and exhibited a stereoselectivity in that (-)-MDMA and (+)-MDA levels were higher than those of enantiomers. The relationship between the dose of ((+)-MDMA and reduction in 5-HT levels was next investigated in SD male, SD female, and Dark Agouti (DA) female rats. These animals exhibit different capabilities of MDMA metabolism. There is a lower level of MDA, the N-demethylated metabolite of MDMA, in female SD rats than in males. Female DA rats are deficient in CYP2D isozymes, one of the enzymes responsible for demethylenation of MDMA to DHMA at pharmacological concentrations of substrate. there was a significant accuulation of MDMA in the brain and plasma of DA rats, but their 5-HT depletion was somewhat attenuated. The results indicated that MDMA ++ was apparently not the single, causative agent for the acute 5-HT depletion, which may also involve a metabolite formed by CYP2D.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8602874     DOI: 10.1016/0006-2952(95)02397-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  36 in total

1.  In vitro metabolism of 3,4-methylenedioxymethamphetamine in human hepatocytes.

Authors:  Corinne Ramaley; Susan C Leonard; Jeffrey D Miller; Denita Takesha-Mashia Wilson; Sai Y Chang; Qingyu Chen; Feng Li; Chengan Du
Journal:  J Anal Toxicol       Date:  2014-03-28       Impact factor: 3.367

2.  L-tyrosine contributes to (+)-3,4-methylenedioxymethamphetamine-induced serotonin depletions.

Authors:  Joseph M Breier; Michael G Bankson; Bryan K Yamamoto
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

3.  Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.

Authors:  Melanie Mueller; Amy K Goodwin; Nancy A Ator; Una D McCann; George A Ricaurte
Journal:  J Pharmacol Exp Ther       Date:  2011-04-14       Impact factor: 4.030

4.  Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance.

Authors:  Una D McCann; Zsolt Szabo; Melin Vranesic; Michael Palermo; William B Mathews; Hayden T Ravert; Robert F Dannals; George A Ricaurte
Journal:  Psychopharmacology (Berl)       Date:  2008-07-27       Impact factor: 4.530

5.  MDMA: on the translation from rodent to human dosing.

Authors:  A Richard Green; Johan Gabrielsson; Charles A Marsden; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2009-01-13       Impact factor: 4.530

Review 6.  Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs.

Authors:  Michael H Baumann; Mohammad O Bukhari; Kurt R Lehner; Sebastien Anizan; Kenner C Rice; Marta Concheiro; Marilyn A Huestis
Journal:  Curr Top Behav Neurosci       Date:  2017

Review 7.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

Review 8.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

9.  Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity.

Authors:  Melanie Mueller; Jie Yuan; Anne Felim; Anne Neudörffer; Frank T Peters; Hans H Maurer; Una D McCann; Martine Largeron; George A Ricaurte
Journal:  Drug Metab Dispos       Date:  2009-07-23       Impact factor: 3.922

10.  Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations.

Authors:  William E Fantegrossi; Naoki Murai; Brian O Mathúna; Nieves Pizarro; Rafael de la Torre
Journal:  J Pharmacol Exp Ther       Date:  2009-03-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.